Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Lymphoid 1

Conditions

Oligodendroglioma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 5Filgrastim 5Magnetic Resonance Spectroscopy 4Specimen Handling 3Radiotherapy 3Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Peripheral Blood Stem Cell Transplantation 2Etoposide 2Drug Therapy 2Cyproheptadine 2Carmustine 2Carboplatin 2Bortezomib 2vorasidenib 1vocimagene amiretrorepvec 1varlilumab 1trametinib 1sonidegib 1selinexor 1sargramostim 1romidepsin 1ribociclib 1poly ICLC 1ixabepilone 1ispinesib 1imetelstat 1exatecan 1etoposide phosphate 1entinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × Eflornithine × Lymphoid × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡